|
|
|
|
|
Vincristine
drug data and news
Vincristine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Vincristine | ||
| Brand Names/Synonyms | Indole alkaloid; LCR; Leurocristine; Onco TCS; Oncovin; VCR; VIN; Vincasar PFS; Vincrex; Vincristina [DCIT]; Vincristine; Vincristine Sulfate; Vincristine Sulfate PFS; Vincristinum [INN-Latin]; Vincrstine; Vincrystine; Vinkristin; 22-Oxovincaleukoblastine; EINECS 200-318-1; Oncovin (1:1 sulfate salt); Vincaleukoblastine, 22-oxo-; Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Z-D-Val-Lys(Z)-OH | ||
| Indication | For treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, acute panmyelosis | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. | ||
| Mechanism Of Action | The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. | ||
| Vincristine News (When available) |
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug ... May 8, 2006 James Le Fanu praises plants, the most important source of the ... May 2, 2006 Teen deserves a gold medal for guts, too May 12, 2006 A Pilot Study With Long Term Follow Up of Hyperbaric Oxygen ... Apr 24, 2006 Inex Pharmaceuticals Closes Hana Biosciences Licensing Agreement May 8, 2006 Hana Biosciences Reports First Quarter 2006 Results May 4, 2006 Biogen Idec Reports First Quarter 2006 Results Apr 26, 2006 Dose-Dense Therapy for NHL Safely Administered with Support of ... Apr 18, 2006 | ||
| Dosage Forms | LIQUID; SOLUTION | ||
| Drug_Category | Antineoplastic Agents; ATC:L01CA02 | ||
| Absorption | Not Available | ||
| Interactions | Interactions for Vincristine: The simultaneous oral or intravenous administration of phenytoin and antineoplastic chemotherapy combinations that included vincristine sulfate has been reported to reduce blood levels of the anticonvulsant and to increase seizure activity. Dosage adjustment should be based on serial blood level monitoring. The contribution of vincristine sulfate to this interaction is not certain. The interaction may result from reduced absorption of phenytoin and an increase in the rate of its metabolism and elimination. | ||
| Toxicity | IVN-RAT LD50 1300 mg/kg; IPR-MUS LD50 5.2 mg/kg | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C46H56N4O10 | ||
| Molecular Weight | 824.958 g/mol | ||
| Smiles String | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O | ||
| Melting Point | 220 °C | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.918 | ||
| Isoelectric Point | 5 | ||
| Biotransformation | Hepatic | ||
| Half Life | 19-155 hours | ||
| Protein Binding [%] | ~75% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Vincristine.html http://www.rxlist.com/cgi/generic3/vincristine.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00495 | ||
| CAS Registry Number | 57-22-7 | ||
| KEGG Compound ID | C07204 | ||
| PubChem ID | SID:148816 | ||
| PharmGKB ID | PA451879 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2143305 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |